Pozen plots tax inversion with $144M Tribute buy; Lilly eyes Q3 European launch for Lantus biosim;

@FiercePharma: Are European investors catching on to the value of animal health? FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA warning letter says Czech company shipped bacteria contaminated APIs to the U.S. Article | Follow @EricPFierce

@CarlyHFierce: U.K. cost watchdogs boost J&J's Stelara ahead of hefty competition. More | Follow @CarlyHFierce

> A week after it brought in new managers to replace founder and CEO John Plachetka, Pozen says it's doing a tax inversion deal with the $144 million buyout of Tribute Pharmaceuticals Canada, moving its official domicile to Ireland. Report

> Eli Lilly & Co.'s ($LLY) diabetes chief, Enrique Conterno, said it plans to roll out its version of Sanofi's ($SNY) blockbuster basal insulin Lantus in Europe in the third quarter. Report

> Bayer's radio-oncology med Xofigo won backing from England's National Institute for Health and Care Excellence as a treatment for prostate cancer. Report

> Cardinal Health plans to buy the generic drug distributor Harvard Drug Group for $1.12 billion to extend its reach in generics and over-the-counter meds. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Medtronic aims for diabetic consumer tech in deals with Samsung, Glooko and connected MiniMed clearance. Article | Follow @FierceMedDev

@VarunSaxena2: 'Heart in a Box' for preserving transplanted organs received $20M in funding. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: NICE sings a different tune for Bayer's prostate cancer drug Xofigo. Story | Follow @EmilyWFierce

> Medtronic touts data in support of FDA approval of the latest MiniMed glucose monitor. Story

> Alibaba founder pumps $142M into Beijing-based devicemaker. Article

Biotech News

@FierceBiotech: Novo Nordisk's diabetes combo beats Lantus in Phase III. Report | Follow @FierceBiotech

@JohnCFierce: UPDATED: Patriots owner Kraft teams up on a $30M antibiotics A round for Spero. News | Follow @JohnCFierce

@DamianFierce: $TEVA chief Erez Vigodman signs his letters to $MYL with initials only, such is his commitment to synergies. | Follow @DamianFierce

> FDA asks experts to weigh in on PCSK9 drugs' market reach for Amgen, Regeneron/Sanofi. Report

> Buzz: Sobi spurns Pfizer's rumored $5B buyout deal. More

Animal Health News

> USDA says deadly avian flu virus on the wane in the Midwest as weather warms. Report

> Nexvet shares rebound on positive data from study of pain drug in cats. Item

> FDA launches safety investigation of controversial raw foods for pets. More

> Cancer immunotherapy tried in pet dogs moves to human trials. Story

> Eli Lilly, Zoetis among stakeholders signing on to White House antibiotics plan. Article

Biotech IT News

> Amazon, Google duke it out for control of cloud genomics. Story

> 10X Genomics poaches David Jaffe from the Broad Institute. Item

> U.K. overrun by requests to opt-out of health data sharing program. Article

> Saama raises $35M to fuel push into life science data analytics. News

> Illumina misses out as U.K. picks interpretation providers for 100K Genomes Project. Report

Pharma Marketing News

> ADA highlights: Novo, Lilly meds top Lantus; Sanofi, AZ tout new combo regimens. More

> Pfizer apologizes to U.K. docs as Lyrica protection campaign hits snag. Report

> AbbVie, J&J gallop toward first-line Imbruvica sales with new survival data. Story

> Never too old to be young, Pfizer says, with new tack on Get Old campaign. Article

> Five digital campaigns that show pharma really can do it. Feature

And Finally... Companies are adopting tech-oriented apps and programs to help fend off diabetes in their employees. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.